Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetics, Oncology, and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EHMT2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EHMT2 Recombinant Protein (SET Domain / Active Catalytic Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic assays. |
View EHMT2 Products |
| Gene Delivery | EHMT2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cellular target engagement assays. |
View EHMT2 Products |
| Benchmark Ab | Anti-EHMT2 Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and immunofluorescence. |
View EHMT2 Products |
| Validator | EHMT2 siRNA Set For target knockdown verification and phenotypic validation. |
View EHMT2 Products |
| Related Target A | EHMT1 (GLP) Forms a functional heterodimer with EHMT2; essential for counter-screening and selectivity assays. |
View EHMT1 Products |
| Related Target B | DNMT1 Cooperates with EHMT2 to maintain DNA methylation and gene silencing; key target for combination therapy studies. |
View DNMT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| EHMT1 vs. EHMT2 Selectivity Screening | High-purity recombinant SET domains for both EHMT1 and EHMT2 available with verified sequence identity. |
| Assay Interference from Impurities | Strictly endotoxin-controlled, ultra-pure protein fractions (>95% by SDS-PAGE) to ensure robust enzymatic activity. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated positive controls included in the workflow. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for orthogonal target knockdown and specificity checks in cellular models. |
Live EHMT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EHMT2 (G9a) therapeutics is intensifying, with major players shifting focus from traditional non-selective methyltransferase inhibitors to highly selective small molecules and targeted protein degraders (PROTACs). As first-generation therapies reach clinical evaluations, the next wave of R&&D is targeting combination strategies, particularly in reversing immunotherapy resistance and treating hematological malignancies through fetal hemoglobin induction.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic institutions, Biotech startups | Solid Tumors, Hematological Disorders | Enzymatic Assay (Need active SET domain recombinant protein) |
| PROTACs (Degraders) | Epigenetic-focused Biopharma | Refractory Cancers, Immunotherapy Resistance | Degradation Kinetic Assay (Need lentivirus for stable cell line expression) |
| Combination Therapies | Global Oncology Consortia | Immune Checkpoint Resistant Tumors | Synergy Validation (Need validated siRNA and pathway-related targets like DNMT1) |